X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (16) 16
cancer (15) 15
index medicus (15) 15
melanoma (14) 14
oncology (12) 12
immunotherapy (11) 11
adult (10) 10
female (10) 10
male (10) 10
middle aged (10) 10
aged (9) 9
immunology (9) 9
article (8) 8
care and treatment (8) 8
aged, 80 and over (7) 7
chemotherapy (7) 7
melanoma - drug therapy (7) 7
metastasis (7) 7
mutation (7) 7
tumors (7) 7
antibodies, monoclonal - administration & dosage (6) 6
melanoma - pathology (6) 6
metastatic melanoma (6) 6
treatment outcome (6) 6
abridged index medicus (5) 5
cytotoxicity (5) 5
expression (5) 5
ipilimumab (5) 5
melanoma - immunology (5) 5
patients (5) 5
research (5) 5
sarcoma (5) 5
antibodies, monoclonal - adverse effects (4) 4
apoptosis (4) 4
cancer therapies (4) 4
cell line, tumor (4) 4
clinical trials (4) 4
dendritic cells (4) 4
disease-free survival (4) 4
drug therapy (4) 4
flow cytometry (4) 4
hematology, oncology and palliative medicine (4) 4
immune system (4) 4
kinases (4) 4
lymphocytes (4) 4
medical colleges (4) 4
medicine (4) 4
medicine, general & internal (4) 4
melanoma - genetics (4) 4
melanoma - metabolism (4) 4
melanoma - therapy (4) 4
monoclonal antibodies (4) 4
neoplasm metastasis (4) 4
pembrolizumab (4) 4
programmed cell death 1 receptor - antagonists & inhibitors (4) 4
safety (4) 4
activation (3) 3
animals (3) 3
antineoplastic agents - adverse effects (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
antitumor immunity (3) 3
cd4-positive t-lymphocytes - metabolism (3) 3
cd8 antigen (3) 3
cd8-positive t-lymphocytes - immunology (3) 3
dose-response relationship (3) 3
drug resistance, neoplasm (3) 3
histocompatibility antigens class ii - metabolism (3) 3
immune response (3) 3
internal medicine (3) 3
kaplan-meier estimate (3) 3
medicine, research & experimental (3) 3
methods (3) 3
mice (3) 3
mice, inbred c57bl (3) 3
monoclonal-antibody (3) 3
patient outcomes (3) 3
peptides - immunology (3) 3
peptides - metabolism (3) 3
signal transduction - drug effects (3) 3
skin cancer (3) 3
survival (3) 3
t cells (3) 3
tolerance (3) 3
young adult (3) 3
anti-pd-1 antibody (2) 2
antibodies (2) 2
antibodies, monoclonal - therapeutic use (2) 2
antibody (2) 2
antigens (2) 2
antigens, cd - immunology (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
autoantigens - immunology (2) 2
autoimmune diseases (2) 2
biopsy (2) 2
bone marrow transplantation - immunology (2) 2
bone neoplasms - mortality (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 4, pp. 375 - 384
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9948, pp. 1109 - 1117
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10043, pp. 488 - 497
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10028, pp. 1629 - 1637
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 954 - 965
Summary Background Addition of a MEK inhibitor to a BRAF inhibitor enhances tumour growth inhibition, delays acquired resistance, and abrogates paradoxical... 
Hematology, Oncology and Palliative Medicine
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 4, pp. 371 - 382
Summary Background Preclinical studies have shown synergistic antitumour activity by inhibition of insulin-like growth factor-1 receptor (IGF-1R) and mTOR. The... 
Hematology, Oncology and Palliative Medicine | INSULIN | RAPAMYCIN | ACTIVATION | ONCOLOGY | ANTIBODY | AKT | REFRACTORY EWING SARCOMA | INHIBITOR | FACTOR-I RECEPTOR | TUMORS | EXPRESSION | Bone Neoplasms - mortality | Receptor, IGF Type 1 - metabolism | Receptor, IGF Type 1 - antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | TOR Serine-Threonine Kinases - metabolism | Drug-Related Side Effects and Adverse Reactions - chemically induced | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Bone Neoplasms - pathology | Drug-Related Side Effects and Adverse Reactions - pathology | TOR Serine-Threonine Kinases - antagonists & inhibitors | Neoplasm Grading | Sarcoma - mortality | Aged, 80 and over | Adult | Female | Bone Neoplasms - drug therapy | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Sarcoma - drug therapy | Sarcoma - pathology | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Sirolimus - administration & dosage | Antibodies, Monoclonal - administration & dosage | Receptor, IGF Type 1 - immunology | Aged | Antimitotic agents | Care and treatment | Chemotherapy | Sarcoma | Product development | Antineoplastic agents | Cancer
Journal Article
Journal of Thoracic and Cardiovascular Surgery, The, ISSN 0022-5223, 2015, Volume 149, Issue 1, pp. 85 - 92
Journal Article
Nature, ISSN 0028-0836, 01/2018, Volume 553, Issue 7688, pp. 347 - 350
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2009, Volume 15, Issue 19, pp. 6267 - 6276
Journal Article
Cancer Discovery, ISSN 2159-8274, 02/2017, Volume 7, Issue 2, pp. 188 - 201
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2015, Volume 51, Issue 11, pp. 1435 - 1443
Abstract Introduction Vemurafenib induces tumour regression in most patients with BRAFV600E -mutant melanoma; eventually, most experience progressive disease... 
Hematology, Oncology and Palliative Medicine | Vemurafenib | BRAF inhibitor | Metastatic melanoma | Braf inhibitor | vemurafenib | metastatic melanoma
Journal Article